Squamous cell carcinoma - I-Squamous Cell Carcinoma
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Squamous cell carcinoma well differentiated ― I-actinic keratosis eseduze iyabonwa.
References
I- Squamous cell carcinoma (SCC) ingumdlavuza wesikhumba wesibili ovame kakhulu e-United States, ngemva kwe- basal cell carcinoma. Ngokuvamile iqala ezilonda eziyingozi ezibizwa ngokuthi actinic keratosis , futhi ingasakazekela kwezinye izingxenye zomzimba. Isizathu esiyinhloko ukuchayeka emisebeni ye-ultraviolet (UV) evela elangeni, enqwabelana ngokuhamba kwesikhathi. Ukwelashwa ngokuvamile kuhilela ukususwa ngokuhlinzwa, ikakhulukazi i-SCC ekhanda nasentanyeni. Ukwelashwa ngemisebe inketho yeziguli ezindala noma lezo ezingakwazi ukuhlinzwa. I-Immunosuppression inyusa ingozi ye-SCC. Nakuba ingavamile, i-SCC ingasakazeka, ikakhulukazi ezigulini ezinamasistimu omzimba abuthakathaka. Ukuhlolwa njalo nokuvikela ilanga kubalulekile kulabo abane-SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) umdlavuza wesibili ovame kakhulu kubantu, futhi izibalo zawo ziyakhuphuka. Nakuba i-CSCC ngokuvamile ibonisa ukuziphatha okuhle komtholampilo, ingasakazeka kokubili endaweni nakwezinye izingxenye zomzimba. Ososayensi bahlonze izindlela ezithile ezihilelekile ekuthuthukisweni kwe-CSCC, okuholela ekwelashweni okusha. Inani eliphakeme lokuguqulwa kwezakhi zofuzo kanye nengozi eyengeziwe ezigulini ezingenawo amandla omzimba kuye kwabangela ukuthuthukiswa kwe-immunotherapy. Lokhu kubuyekezwa kubheka izimpande zofuzo ze-CSCC kanye nokwelashwa kwakamuva okuqondiswe kuma-molecule athile kanye namasosha omzimba.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Ukuxilongwa Nokwelashwa
#Dermoscopy
#Skin biopsy